UroGen Pharma (STU:UR8) Accumulated other comprehensive income (loss) : €0.05 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is UroGen Pharma Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. UroGen Pharma's Accumulated other comprehensive income (loss) for the quarter that ended in Dec. 2024 was €0.05 Mil.

UroGen Pharma's quarterly Accumulated other comprehensive income (loss) increased from Jun. 2024 (€-0.03 Mil) to Sep. 2024 (€0.21 Mil) but then declined from Sep. 2024 (€0.21 Mil) to Dec. 2024 (€0.05 Mil).

UroGen Pharma's annual Accumulated other comprehensive income (loss) increased from Dec. 2022 (€-0.10 Mil) to Dec. 2023 (€0.01 Mil) and increased from Dec. 2023 (€0.01 Mil) to Dec. 2024 (€0.05 Mil).

UroGen Pharma Accumulated other comprehensive income (loss) Historical Data

The historical data trend for UroGen Pharma's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UroGen Pharma Accumulated other comprehensive income (loss) Chart

UroGen Pharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accumulated other comprehensive income (loss)

Get a 7-Day Free Trial

0.22

-0.02

-0.10

0.01

0.05

UroGen Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Accumulated other comprehensive income (loss)	Get a 7-Day Free Trial															0.01	-0.03	-0.03	0.21	0.05

UroGen Pharma Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

UroGen Pharma Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of UroGen Pharma's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

UroGen Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UroGen Pharma Ltd (STU:UR8) » Definitions » Accumulated other comprehensive income (loss)

Comparable Companies

Traded in Other Exchanges

URGN:USA 0XOD:UK

Address

400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540

Website

https://www.urogen.com

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

UroGen Pharma Headlines

No Headlines